Mycosis fungoides (MF) is a cutaneous lymphoma of presumed T-helper cell origin. It usually presents with patches and infiltrated plaques, but a wide range of atypical forms have also been described. We report a 48-year-old man who had a 2-year history of a pruritic, warty plaque on the right palm with surrounding poikilodermatous changes. He subsequently developed additional macules of poikiloderma atrophicans vasculare (PAV) on the right upper limb and abdomen. Biopsies from the arm showed poikilodermatous changes, and the warty plaque had features of MF. Verrucous or hyperkeratotic lesions appear to be an uncommon presenting feature of MF with few case reports in the literature to date. This presentation may be associated with considerable diagnostic delay, and MF should be considered in the differential diagnosis of acquired verrucous lesions. This case also illustrates that PAV may herald cutaneous malignancy, and that patients with this condition require close follow up.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1365-2230.1996.tb00063.x | DOI Listing |
Skinmed
January 2025
Department of Skin & VD, Civil Hospital, BJ Medical College, Ahmedabad, Gujarat, India.
Mycosis fungoides (MF) is a neoplasm of the immune system. It is a cutaneous lymphoma originating in the peripheral epidermotropic T-cells, specifically the memory T-cells (CD45RO+). The etiology of MF is indefinite, but various factors, such as genetic and epigenetic abnormalities, environmental and occupational exposure to chemicals, infections, and cytokines (interleukin [IL]-2, IL-4, etc.
View Article and Find Full Text PDFJ Invest Dermatol
December 2024
Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA. Electronic address:
An Bras Dermatol
December 2024
Dermatology Department, Şişli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Seyrantepe, İstanbul, Turkey.
Background: There are few studies in the literature comparing the effectiveness of topical treatments in early-stage mycosis fungoides (MF).
Objectives: It was aimed to evaluate the clinical efficacy, side effects and topical treatment compliance with bexarotene or clobetasol propionate in early-stage MF.
Methods: A total of 40 patients with stage IA-IB MF were enrolled in the study.
Front Med (Lausanne)
December 2024
Division of Radiation Oncology, University of Montreal, Montreal, QC, Canada.
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), representing the majority of all lymphomas arising in the skin. The disease treatment focuses on managing symptoms and preventing disease evolution. To date, there is no gold standard for MF-CTCL treatment.
View Article and Find Full Text PDFJ Dtsch Dermatol Ges
December 2024
Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Clinic, University Hospital of the Ruhr University Bochum, Bochum, Germany.
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of the heterogeneous group of cutaneous T-cell lymphomas (CTCL). With the expansion of the biologic treatment landscape, new treatment options have become available in recent years, most notably the C-C chemokine receptor 4 (CCR4)-directed monoclonal antibody mogamulizumab. Based on the phase III pivotal trial, mogamulizumab is recommended by the German S2k guidelines for the second-line treatment of stage IB and above SS and MF, after at least one prior systemic therapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!